In a nutshell This study investigated the effects of stem cell transplant and anti-cancer drug treatment for Multiple Myeloma. Stem cell transplant appeared to increase survival in patients with Multiple Myeloma. Some background Multiple myeloma (MM) is a type of cancer in which red blood cells over produce antibodies. Stem cell transplant is a common...Read More
Type(s) of biological/targeted therapy-Lenalidomide Posts on Medivizor
In a nutshell This study investigated the effects of lenalidomide/dexamethasone (Revlimid/Dexasone) combination treatment in relapsed multiple myeloma. The main finding was that the type of relapse may predict how a patient responds to lenalidomide/dexamethasone treatment. Some background Common treatments for multiple myeloma (MM) include...Read More
What is the benefit of adding ixazomib to lenalidomide and dexamethasone for relapsing/refractory multiple myeloma?
In a nutshell This study investigated the effects of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone (Dexasone) for patients with unresponsive multiple myeloma. The main finding was that patients receiving ixazomib plus lenalidomide and dexamethasone survived longer without worsening of cancer (progression-free...Read More
In a nutshell This paper reviewed the effect of thearpies that act on the immune system on the risk of infection. The study concluded that patients receiving these drugs are at a high risk of serious infection. Some background Treatment for multiple myeloma now generally includes immunomodulators and stem cell transplantation....Read More
In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...Read More
In a nutshell This study examined the effects of pomalidomide (Pomalyst) in combination with bortezomib (Velcade) and dexamethasone (Decadron) in patients with relapsed or refractory multiple myeloma. This treatment combination was considered safe and effective for previously treated multiple myeloma. Some background Standard treatment for...Read More